The Fabry Exchange: Optimizing Diagnosis and Treatment Initiation
This webcast was recorded during a live symposium at the WORLDSymposium Meeting in San Diego, CA, USA, on February 7, 2018. During the symposium, experts from around the world discussed the key clinical questions and controversies in the diagnosis of Fabry disease and the future direction of clinical management. They also addressed the consequences of delayed diagnosis and treatment initiation, provided guidance on understanding available diagnostic options, and discussed genotype–phenotype correlations and their significance for daily clinical practice.
This activity has been designed to meet the educational needs of clinical geneticists, pediatricians, nephrologists, internists, neurologists, cardiologists, and other allied health care professionals responsible for the diagnosis, treatment, and management of patients with lysosomal diseases.
Upon completion of this activity, participants should be better able to:
- Recognize the consequences of delayed diagnosis and treatment initiation for patients with Fabry disease
- Describe key diagnostic algorithms for the evaluation of patients with Fabry disease, and discuss genotype-phenotype correlations
David G. Warnock, MD
Alberto Ortiz, MD, PhD
Gavin Y. Oudit, MD, PhD
Disclosure of Conflicts of Interest
It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
|Faculty||Relationship Identified With:|
|David G. Warnock, MD|
Consultant/Advisor: Sanofi Genzyme, Protalix Ltd., Idorsia Pharmaceuticals Ltd, Reata Pharmaceuticals, Inc.Stock Ownership: Reata Pharmaceuticals, Inc.
|Alberto Ortiz, MD, PhD|
Consultant/Advisor: Sanofi Genzyme
Speakers Bureau: Amicus Therapeutics, Inc., Sanofi Genzyme, ShireGrant/Research Support: Sanofi Genzyme
|Gavin Y. Oudit, MD, PhD|
Speakers Bureau: Sanofi GenzymeGrant/Research Support: Sanofi Genzyme
Non-faculty: Sandy Breslow; Alison Kemp; Bernard M. Abrams, MD; Joke Artmanni; Megan Cannon, PhD; Marijke Verhaaf; hereby state that neither they nor their spouse/life partner have had any financial relationships to products or devices with any commercials interest related to the content of this activity of any amount during the past 12 months.
This activity has been supported by an independent educational grant from Sanofi Genzyme.
Jointly provided by the Elsevier Office of Continuing Medical Education and Excerpta Medica.
CME Credit (Physicians)
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Elsevier Office of Continuing Medical Education and Excerpta Medica. The Elsevier Office of Continuing Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
The Elsevier Office of Continuing Medical Education designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CME INQUIRIES/SPECIAL NEEDS
For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.
Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education, Excerpta Medica and Sanofi Genzyme do not recommend the use of any agent outside of the labeled indications.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
- 0.50 AMA PRA Category 1 Credit(s)™
- 0.50 Non-physician